Conditions: Neoplasms, Unknown Primary
Keywords: Neoplasms, Unknown Primary
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 48
Healthy volunteers: no

Brief summary:
In this phase II trial, we will evaluate the feasibility and efficacy of the oxaliplatin/capecitabine combination in patients who have had one previous chemotherapy regimen for the treatment of carcinoma of unknown primary site. Patients who are relapsed after a previous response to treatment will be eligible, as well as those who were refractory to first-line therapy.

Detailed description:
All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 PO BID was administered on days 1-14 of each cycle.

Arms:
arm 1: All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 by mouth twice daily was administered on days 1-14 of each cycle.

Interventions: intervention 1: Oxaliplatin intervention 2: Capecitabine
Intervention descriptions: intervention 1: 130 mg/m2 IV day 1 of 21 day cycle intervention 2: 1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle

Protocol document: